Paola Ghanem
Overview
Explore the profile of Paola Ghanem including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Resch E, Makri S, Ghanem P, Baraban E, Cohen K, Cohen A, et al.
NPJ Precis Oncol
. 2025 Feb;
9(1):48.
PMID: 39984702
Enhancer of zeste homolog 2 (EZH2) is an essential epigenetic regulator of H3K27 histone methylation and is mutated or overexpressed in a wide variety of cancers. In melanoma, EZH2 overexpression...
2.
Nakazawa M, Harada G, Ghanem P, Bubie A, Kiedrowski L, Murray J, et al.
Cancer Res Commun
. 2024 Feb;
4(3):786-795.
PMID: 38407352
Significance: In a large-scale, contemporary cohort of patients with advanced ALK-positive NSCLC, we evaluated molecular characteristics and their impact on acquired resistance mutations and clinical outcomes. Our findings that certain...
3.
Ghanem P, Murray J, Hsu M, Guo M, Ettinger D, Feliciano J, et al.
Clin Lung Cancer
. 2023 Dec;
25(2):109-118.
PMID: 38161136
Objectives: Understand from a real-world cohort the unique clinical and genomic determinants of a durable response to immune checkpoint inhibitors (ICIs). Materials And Methods: This is a retrospective study of...
4.
Ghanem P, Fatteh M, Kamson D, Balan A, Chang M, Tao J, et al.
Front Med (Lausanne)
. 2023 Dec;
10:1254955.
PMID: 38143440
Background: Despite the putatively targetable genomic landscape of high-grade gliomas, the long-term survival benefit of genomically-tailored targeted therapies remains discouraging. Methods: Using glioblastoma (GBM) as a representative example of high-grade...
5.
Ghanem P, Murray J, Marrone K, Scott S, Feliciano J, Lam V, et al.
RMD Open
. 2023 Nov;
9(4).
PMID: 37914179
Purpose: Concomitant autoimmune rheumatic diseases (ARD) can add morbidity and complicate treatment decisions for patients with lung cancer. We evaluated the tumour characteristics at diagnosis and clinical outcomes in lung...
6.
Botsis T, Murray J, Ghanem P, Balan A, Kernagis A, Hardart K, et al.
JCO Clin Cancer Inform
. 2023 Apr;
7:e2200108.
PMID: 37040583
Purpose: Precision oncology mandates developing standardized common data models (CDMs) to facilitate analyses and enable clinical decision making. Expert-opinion-based precision oncology initiatives are epitomized in Molecular Tumor Boards (MTBs), which...
7.
El Sabeh M, Kassir M, Ghanem P, Saifi O, El Hadi D, Khalifeh Y, et al.
J Biosoc Sci
. 2023 Feb;
55(3):592.
PMID: 36803661
No abstract available.
8.
Tfaily M, Ghanem P, Farran S, Dabdoub F, Kanafani Z
Sci Rep
. 2022 Nov;
12(1):19184.
PMID: 36357432
Whipple surgery is associated with a high risk of surgical sites infections (SSIs). Nutritional deficiency has been associated with an increased risk of wound infections. This study aims at exploring...
9.
Scharpf R, Balan A, Ricciuti B, Fiksel J, Cherry C, Wang C, et al.
Cancer Res
. 2022 Sep;
82(21):4058-4078.
PMID: 36074020
Significance: The complex genomic landscape of RAS-mutant tumors is reflective of selection processes in a cancer lineage-specific and context-dependent manner, highlighting differential therapeutic vulnerabilities that can be clinically translated.
10.
Guo M, Murray J, Ghanem P, Voong K, Hales R, Ettinger D, et al.
Clin Lung Cancer
. 2022 Aug;
23(7):620-629.
PMID: 36045016
Background: Consolidation durvalumab immunotherapy following definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC) improves overall survival. As therapeutic options for patients with KRAS-driven disease evolve, more...